Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
90.37
+2.57 (2.93%)
Mar 4, 2026, 1:01 PM EST - Market open
Mirum Pharmaceuticals Revenue
In the year 2025, Mirum Pharmaceuticals had annual revenue of $521.31M with 54.74% growth. Mirum Pharmaceuticals had revenue of $148.93M in the quarter ending December 31, 2025, with 49.81% growth.
Revenue (ttm)
$521.31M
Revenue Growth
+54.74%
P/S Ratio
10.46
Revenue / Employee
$1,401,376
Employees
372
Market Cap
5.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 521.31M | 184.42M | 54.74% |
| Dec 31, 2024 | 336.89M | 150.51M | 80.76% |
| Dec 31, 2023 | 186.37M | 109.31M | 141.85% |
| Dec 31, 2022 | 77.06M | 57.92M | 302.66% |
| Dec 31, 2021 | 19.14M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.73B |
| Caris Life Sciences | 812.03M |
| Rhythm Pharmaceuticals | 189.76M |
| Protagonist Therapeutics | 46.02M |
| CG Oncology | 4.04M |
| CRISPR Therapeutics AG | 3.51M |
MIRM News
- 6 days ago - Mirum Pharmaceuticals, Inc. (MIRM) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update - Business Wire
- 8 days ago - Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
- 13 days ago - Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 - Business Wire
- 21 days ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 27 days ago - Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome - Business Wire
- 27 days ago - Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) - Business Wire
- 4 weeks ago - Top 3 Health Care Stocks That May Implode In Q1 - Benzinga